Loading...
Loading...
PCVX| Name | Value |
|---|---|
| Revenues | 14.4M |
| Cost of Revenue | 2.9M |
| Gross Profit | 11.5M |
| Operating Expense | 118.7M |
| Operating I/L | -121.7M |
| Other Income/Expense | 15.9M |
| Interest Income | 17.6M |
| Pretax | -180.8M |
| Income Tax Expense | 14.6M |
| Net Income/Loss | -180.8M |
Vaxcyte, Inc. is a clinical-stage biotechnology company specializing in the development of novel protein vaccines to prevent and treat bacterial infectious diseases. The company's lead vaccine candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine currently in Phase 1/2 clinical trials for the treatment of invasive pneumococcal disease and pneumonia. Additionally, Vaxcyte is developing VAX-XP to address emerging strains and antibiotic resistance, VAX-A1 for Group A Strep, and VAX-PG targeting the keystone pathogen responsible for periodontitis.
